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Abstract 
 
Background 
Although financing represents a critical component of health system strengthening and also a defining 
concern of efforts to move towards universal health coverage, many countries lack the tools and capacity to 
plan effectively for service scale-up. As part of a multi-country collaborative study (the Emerald project), we 
set out to develop, test and apply a fully integrated health systems resource planning and health impact tool 
for mental, neurological and substance use (MNS) disorders.   
Methods 
A new module of the existing UN strategic planning OneHealth Tool (OHT) was developed, which identifies 
health system resources required to scale-up a range of specified interventions for MNS disorders and also 
projects expected health gains at the population level. We conducted local capacity-building in its use, as 
well as stakeholder consultations, then tested and calibrated all model parameters, and applied the tool to 
three priority mental and neurological disorders (psychosis, depression and epilepsy) in six low and middle-
income countries.  
Results  
Resource needs for scaling-up mental health services to reach desired coverage goals are substantial 
compared to the current allocation of resources in the six represented countries but are not large in 
absolute terms. In four of the Emerald study countries (Ethiopia, India, Nepal and Uganda), the cost of 
delivering key interventions for psychosis, depression and epilepsy at existing treatment coverage is 
estimated at US$ 0.06-0.33 per capita of total population per year (in Nigeria and South Africa it is US$ 
1.36-1.92). By comparison, the projected cost per capita at target levels of coverage approaches US$ 5 per 
capita in Nigeria and South Africa, and ranges from US$ 0.14-1.27 in the other four countries. 
Implementation of such a package of care at target levels of coverage is expected to yield between 291-
947 healthy life years per one million population, which represents a substantial health gain for the currently 
neglected and under-served sub-populations suffering from psychosis, depression and epilepsy.  
Conclusions 
This newly developed and validated module of OneHealth tool can be used, especially within the context of 
integrated health planning at the national level, to generate contextualised estimates of the resource needs, 
costs and health impacts of scaled-up mental health service delivery.    
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Introduction  
A critical component of health system strengthening, which underlies the universal health coverage 
agenda, is financing (WHO, 2010). Health financing is a far-reaching topic that addresses questions not 
only about what services to purchase, but also how resources can be best generated and pooled in a fair 
and sustainable way. An ongoing research program called Emerald (Emerging mental health systems in 
low- and middle-income countries) is investigating a number of such questions as they pertain to mental 
health services, including the adequacy of resources for mental health, fairness in financial contributions to 
the costs of care, and the financial and economic impact of improved access to services (Semrau et al, 
2015). In this study, we  focus on the first of these, which concerns the adequacy of resources. Mental 
health remains a highly underfunded area of health system development, attracting less than 1% of the 
US$ 32 billion spent on official development assistance for health in 2013 (Gilbert et al, 2015) and 
manifesting itself in very low levels of reported government spending (of less than US$ 2 per capita in low- 
and middle-income countries; WHO, 2015). Many low- and middle-income countries do not have – or are 
unable to report – data on mental health expenditure; for example, none of the six countries participating in 
the Emerald study – Ethiopia, India, Nepal, Nigeria, South Africa and Uganda – were able to provide a 
breakdown of inpatient and outpatient mental health expenditures in the recent WHO Mental Health Atlas 
2014 survey (WHO, 2015). 
Estimation of the human, physical and financial capital needed to develop or scale-up prioritised 
interventions is a task that can usefully be undertaken in order to demonstrate the existing funding gap and 
to indicate how it could be bridged over time. Previous work has shown that the cost of scaling-up an 
intervention package for psychosis, bipolar disorder, depression and harmful alcohol use ranged from US$ 
1.85 to US$ 2.60 per person per year in low-income countries and US$ 3.20 to US$ 6.25 per year in lower 
middle-income countries (Chisholm, Lund and Saxena, 2007). Recent work focused more specifically on 
the resources needed to scale-up mental health plans in primary health care at the district level, and 
estimated a cost of less than US$ 1 per head of population in the four low- and lower-middle-income 
countries represented in the study (Chisholm et al, 2015). Two important limitations of such analyses, 
however, are that no account is taken of the health system constraints that limit scale-up efforts in practice 
(such as the availability of skilled workers), and there is no estimate made of the expected health impact 
associated with each year of scale-up. Furthermore, health planners at the country level have, to date, 
lacked access to appropriate analytical tools for undertaking, in the context of overall national health plans, 
an integrated approach to their own mental health resource need assessments (as part of a policy of 
moving towards universal health coverage, for example). 
In this study, therefore, we set out to develop, test and apply a fully integrated health systems resource 
planning and health impact tool for mental, neurological and substance use (MNS) disorders.   
Methods  
Development of OneHealth Tool module on MNS Disorders   
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In order to ensure that the development of national mental health plans is carried out within a framework of 
overall health system capacity assessment, and to take into account financial sustainability and outcomes-
based planning, we developed and populated a mental health module for integration within the OneHealth 
systems planning tool (OHT). OneHealth is a software tool that has been developed by international costing 
experts from WHO and other UN agencies to strengthen health system analysis, costing and financing 
scenarios at the country level (http://www.who.int/choice/onehealthtool; Stenberg and Chisholm, 2012). It 
achieves this by bringing together disease-specific planning (for mental disorders and other diseases) and 
health systems planning (e.g. modules for human resources, logistics, and other health system ‘building 
blocks’). OHT builds on previous costing tools that have been developed in the context of low- and middle-
income countries for a number of communicable and non-communicable health conditions, but takes the 
crucial next step of harmonising these efforts and drawing out the shared health system costs that appear 
in each of these vertically aligned costing tools. 
 
In terms of the conceptual and technical development of this new module within OneHealth, significant time 
and effort was spent implementing a workable mechanism for capturing the cumulative impact of scaled-up 
mental health care interventions, since most of the health effects of such interventions relate to 
improvements in morbidity or disability (as opposed to saving lives); the selected metric for summarising 
these health effects at the population level was healthy life years gained (equivalent to disability-adjusted 
life years averted, where one DALY can be thought of as one lost year of healthy life; 
http://www.who.int/healthinfo/global_burden_disease/metrics_daly/en/).  Healthy life years were computed 
with reference to country-specific life tables that are already built into the model, and reflect the combined 
time spent by the population in a particular state of health with a known degree (or free) of disability. 
Disability levels were drawn from the Global Burden of Disease 2010 study (Salomon et al, 2012). 
Implementation or scale-up of an effective intervention in the population was modelled to reduce the time 
spent in a disabling state, either by reducing prevalence (e.g. by decreasing the number of new cases or by 
increasing the rate of remission), or by improving the level of functioning of people with the condition in 
question. For example, a key effect of managing psychosis with anti-psychotic drugs and psychosocial 
treatment is to control symptoms and enhance functioning, while depression treatment mainly has the 
effect of reducing the duration of an episode (equivalent to increasing the remission rate).  
 
Health impact estimates were developed for MNS disorders and interventions that are covered in the 
WHO’s mental health gap action programme (mhGAP) Intervention Guide (WHO, 2010). Although this 
Intervention Guide covers evidence-based intervention strategies for at least eight disorders (from 
developmental and behavioural disorders in childhood, to dementia in older age), initial country-level testing 
and calibration was restricted to three conditions considered by the participating countries to represent high 
priority disorders: psychosis, depression and epilepsy. Default estimates for deriving the population-level 
health impact of specific interventions were based on UN population projections, the latest Global Burden 
of Disease prevalence estimates for 2010 (Whiteford et al, 2013), and previous reviews or analyses of 
clinical outcomes and cost-effectiveness (Hyman et al, 2006; Chisholm and Saxena, 2012; Patel et al, 
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2015). Web Appendix A provides a summary of default intervention effects for psychosis, depression and 
epilepsy (which countries were encouraged to overwrite with local data if available).   
 
Treatment rates and patterns for specific interventions relied on previous cost-effectiveness studies and 
resource need profiles garnered from existing treatment guidelines and costing tools (WHO, 2010; 
Chisholm and Saxena, 2012; Chisholm et al, 2015). Key categories of health service use were: drug and 
supply costs (e.g. daily dose of a generically produced, first-line anti-psychotic or anti-epileptic medication); 
ambulatory contacts with mental health or general health workers (such as psychologists, counsellors and 
community health workers); and hospital-based outpatient / inpatient care. In addition, programme-level 
resource needs were identified, including overall programme management and administration, as well as 
training (in the use of mhGAP intervention guide, for example). Default drug prices were taken from the 
International Drug Price Indicator Guide, while country-specific unit costs of inpatient and outpatient care 
were taken from WHO-CHOICE (http://www.who.int/choice/country/country_specific). Total costs of 
scaling-up an intervention in a given year for a country were derived by multiplying resource use needs by 
their respective unit costs to give a cost per case, which was then multiplied by the total number of cases 
expected to receive a particular intervention (given by the prevalence of the disorder multiplied by the rate 
of treatment coverage of specific intervention strategies in the population). That is, total cost = Population * 
Prevalence rate * Coverage increase * Treatment cost per case. 
 
OHT capacity-building and country-level adaptation in Emerald countries:  
Once a working tool had been developed, it was applied to the context of each of the six participating 
Emerald countries.  As shown and described elsewhere, indicators of development, health resources, and 
the mental health system vary substantially across the six Emerald countries (Semrau et al, 2015); for 
example, in Ethiopia one psychiatrist serves on average a population of over two million persons, 
compared to less than 400,000 in India and South Africa.  A series of technical workshops were undertaken 
in participating countries in order to build local capacity in the adaptation and use of the MNS module of 
OHT. These workshops were facilitated by cross-country partners responsible for the development and 
validation of the tool, and were attended by local Emerald research team members as well as health 
service planners and experts from central and local governments. A series of presentations were 
developed for these workshops, together with practical exercises for actually using the software (available 
on request from the authors).   
Working with local team members and other national staff, and with support from cross-country partners, 
appointed country focal points undertook a process of contextualising the input data that should be entered 
into OHT to best reflect local data, experiences and priorities. This process consisted of two main elements: 
1) strategic-level consideration involving consultation with an expert group of national planners, policy-
makers and programme managers concerning the specification of appropriate mental health care packages 
and scenarios; current and target coverage levels for specific intervention strategies; and the period of 
scale-up (see Table 1 for the results of decisions taken, based on locally available data if available but 
more often relying upon expert opinion in the absence of such data); and 2) clinical-level consideration of 
average or expected resource use profiles for different disorders and interventions; efficacy / adherence 
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estimates for specific intervention strategies; and unit costs and prices for health care services and 
commodities, such as for staff salaries, outpatient visits and psychotropic medications. For these latter data 
inputs, the research team identified and used local data sources and, where applicable, over-wrote default 
values present in the tool. A data checklist was developed and disseminated in order to facilitate and 
document the process of data contextualisation. A representative example of the contextualisation process 
followed in one country is provided in Box 1. Once each country contextualised the tool to the extent 
possible, results could be presented to and discussed with local health policy makers, planners and other 
stakeholders.  
Application and use of the MNS module in OHT   
Application of the MNS module of the OneHealth tool in the six participating Emerald countries produced 
new estimates of the resource needs, costs and health impacts of scaled-up delivery of their specified 
intervention packages (see Results section below); each country’s finalised estimates, including all 
assigned input parameters as well as detailed model outputs, were saved as a discrete projection file that 
could be opened, reviewed and shared with other project team members (or other OHT users). Following 
further testing and validation, the module has now been made publicly available for download and use (in 
any country) at the following URL: http://spectrumbeta.futuresinstitute.org/. Users are able to generate a new 
projection for their own country setting, specifying the diseases and interventions to be included as well as 
the scale-up period and (current and target) coverage levels to be utilised. Following direct entry of hospital 
unit costs, salary information and programme management and training costs into the tool, as well as 
revision as needed for any other key data inputs, users can view computed output relating to the costs and 
health impacts of mental health service scale-up in their local setting.  It is anticipated that the tool can and 
will be used by health planners in national health agencies and by health system researchers.  A detailed 
user manual dedicated to the MNS module and its operationalization has been developed (available at 
https://spectrummodel.zendesk.com/forums) to facilitate its deployment.  
 
Results  
For the purposes of concise, consistent and comparable reporting across the six participating Emerald 
sites, results presented below are restricted to selected output parameters of the modelling process. All 
cost values have been converted into US dollars for ease of interpretation and comparison, but in the 
context of ongoing policy dialogue local currency values are also being used.   
OHT configuration 
Table 1 provides an overview of the interventions modelled for psychosis, depression and epilepsy in each 
country, and also shows the baseline and target coverage levels set, based on a situational analysis of 
service availability and expert opinion regarding the target level that can be reasonably expected to be 
attained over the scale-up period.  The scale-up period was chosen by each country team and ranged 
between 5-7 years in length; four of the six sites selected 2020 as the final, target year for scale-up. As can 
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be seen, current coverage levels are generally very low, indicating the enormous treatment gap for these 
key disorders in the populations of these (and most other) low- and middle-income countries. Target 
coverage levels, by contrast, are set relatively high, and represent ambitious goals for rapid scale-up of 
service coverage, especially within such a limited period of time. These target coverage levels have a 
crucial impact on the expected costs and health impacts of increased treatment coverage, and are likely to 
be a key topic of discussion in future discussions and interactions with government health planners.  
OHT output: Estimated costs of scale-up 
Web Appendix Tables B-D provide a breakdown of costs by priority disorder for drugs and supplies, 
ambulatory and outpatient care, and inpatient care, respectively. These represent the total resource 
requirements in each year of scale up, based on the contextualised estimates of what each element of this 
package of care should comprise in the local situation. They illustrate well the substantial monetary 
resources that need to be made available if the stated coverage goals are to be reached. At target 
treatment coverage levels in Nigeria, for example, over US$ 200 million would be required in terms of drugs 
and supplies, a further US$ 200 million for ambulatory care and outpatient services, and nearly $500 million 
for inpatient services. By 2018, however, the population of Nigeria is projected to reach 200 million, so 
when considered on a per capita or proportionate basis these amounts appear more realistic (< US$ 5 per 
capita or < 5% of projected health spending), particularly if a steady incremental approach is taken to 
budgetary resource allocation. Programmatic costs (in particular training, supervision and programme 
administration or management) can be found in Web Table E; these resources are shared across specific 
disease entities; for example, an mhGAP training course can cover psychosis, depression and epilepsy.  
Figure 1 shows the breakdown of costs between these different categories of resource need for the scale-
up period as a whole. There are stark differences in the expected contribution of different service elements 
to overall costs of provision; for example, essential psychotropic drugs absorb a large share of overall costs 
in the three low-income countries (Ethiopia, Nepal and Uganda), while the proportion of total costs taken up 
by inpatient services ranges from less than 5% (in Ethiopia and South Africa) to over 80% (in India). This 
pattern of costs reflects the fact that traded goods such as psychotropic medicines are relatively more 
expensive to purchase in low-income settings, while non-traded goods that go into clinical care (including 
human resources) are relatively low cost compared to middle-income countries. 
Table 2 brings together all these cost elements and expresses them both in total terms (per year) and also 
per head of population. The latter metric is particularly useful for looking across countries because it 
standardises for population size. In four of the Emerald study countries (Ethiopia, India, Nepal and 
Uganda), the cost of delivering key interventions for psychosis, depression and epilepsy at existing 
treatment coverage (in the baseline year) is estimated at US$ 0.06-0.33 per capita of total population (in 
Nigeria and South Africa it is US$ 1.36-1.92). By comparison, the projected cost per year at target levels of 
coverage approaches US$ 5 per capita in Nigeria and South Africa, and ranges from US$ 0.14-1.27 in the 
other four countries.  
OHT output: Estimated health impacts of scale-up 
 
 
8 
 
 
Table 3 shows the health impact or implications of substantially scaled-up coverage of included 
interventions, expressed in terms of healthy life years. As can be seen, there is a short lag between greater 
uptake of services and consequent reductions in the prevalence or disability associated with these 
disorders, which is partly due to the exponential pattern of scale-up chosen by countries (this pattern 
assumes a slow start as resources are mobilised and staff are trained, and a rapid increase in the final 
years of the scale up period). The total size of the health impact will evidently vary with the interventions 
chosen, as well as starting and target levels of coverage, but across the six countries the total, cumulative 
health gains amounted to more than two million extra healthy life years. In the final year of each country’s 
projection, at which point target coverage levels are assumed to have been reached, the number of healthy 
life years gained per one million population ranged between 291 in India to 947 in Uganda. Depression 
accounted for the largest proportion of generated public health gain, with the exception of Nigeria, where 
epilepsy generated the greatest number of healthy life years.   
Discussion  
In the face of a large disease burden and treatment gap, the Emerald project aims to generate new 
understanding and insights into the current extent of financial protection and service provision in a range of 
LMIC, as well as future resource needs and mechanisms for moving closer towards the goal of universal 
health coverage for MNS disorders. The component of this broader research agenda presented here has 
been concerned with preparing and implementing a tool capable of informing local policy makers about the 
resource needs and costs of scaling up mental health services in their local populations. Following the 
initial development of a bespoke module, its incorporation into the OneHealth strategic planning tool, and 
its subsequent use in six low- and middle-income countries, it can be concluded that such a tool is now 
ready and available for use in other LMICs.  
Technical capacity in the use of the tool remains a concern, however. Although a manual and other 
materials have been developed to enable new users to familiarise themselves with the OneHealth tool 
generally and the MNS module more specifically, the acquired experience of testing it out in Emerald 
countries suggests that expertise in its deployment only comes about after dedicated training, prolonged 
practice and follow-up support from its developers (or their consultants). This is especially true for 
considering health system components, such as infrastructure, logistics, governance and fiscal space, 
which are an integral part of the tool but require such a breadth of information and knowledge about health 
systems and plans that it can be a challenge to populate and use. Moreover, identification and 
measurement of shared health system costs is most applicable to a genuine sector-wide resource need 
assessment that covers many or all diseases (as well as any underlying preventable risk factors), and less 
so for a programme-oriented analysis such as that aimed for in the current developmental phase. A further 
issue concerns the development and distribution of version updates of the OHT software, which particularly 
in the latter stages of testing and calibration caused a number of compatibility problems that led to delays 
and confusion among country-based users. 
A second broad concern relates the available evidence in these countries on a number of domains. These 
include epidemiological data on the burden and course of MNS disorders, the extent of current coverage 
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and expenditure, and the evidence base for locally adapted cost-effective interventions. While the current 
tool makes use of the best available local evidence, further iterations of this tool will need to draw on new 
and better quality evidence as it becomes available.  
Nevertheless, and due to the capacity-building activities made possible through Emerald project resources, 
new estimates of the resource needs, costs and health impacts of scaled-up mental health service delivery 
have been generated. Results of this estimation exercise indicate that the resource needs for scaling-up 
mental health services need not be substantial, particularly if priority disorders and cost-
effective intervention strategies are judiciously selected. Using a spreadsheet-based tool for estimation, a 
separate costing study undertaken at the district level in five of the Emerald countries came to similar 
estimates of cost, for example showing that the cost per capita for delivering a specified package of 
interventions at target coverage levels ranged from US$ 0.39-0.69 per capita in low-income countries such 
as Ethiopia and Uganda (Chisholm et al, 2015). 
The health returns on such an investment are substantial, as demonstrated by the additional number of 
healthy life years that are generated over the scaling-up period. Such information on the costs and health 
impacts of scale-up provides important evidence that can be brought to bear in dialogue with health 
planners and policymakers at the national level, particularly in the context of increased policy attention to 
the rising burden of noncommunicable diseases. In Ethiopia, for example, an earlier cost estimation 
exercise helped to articulate the resource requirements underlying the objectives of a new Mental Health 
strategy (Federal Democratic Republic of Ethiopia Ministry of Health, 2012), while the ongoing work using 
OHT provided a timely analysis as the national government sought to implement an ambitious plan of 
mental health scale up across the country. Similarly in India, where a national mental health plan has just 
been launched, the findings from this work can make a useful contribution to state-level deliberations on the 
implementation of this plan, especially in Madhya Pradesh where the local Emerald research team is 
based. 
Estimates reported herein represent an initial set of projections, based on locally available evidence and 
the informed inputs of local experts; however, such estimates are subject to further discussion, review and 
revision as planning cycles and political processes evolve. Looking ahead, therefore, plans are in place to 
further engage with local planners and policy makers in each of the countries via policy workshops, where 
key findings from this work can be presented and discussed. New projections will be prepared in the light of 
changes to policies and plans, such as revised target coverage levels or lengthened implementation 
periods. Modelling of other MNS disorders in certain countries where these have been identified as a key 
priority or as an integral component of national mental health strategies can also be undertaken. For 
example, bipolar disorder would be included in future projections for Ethiopia, and alcohol dependence in 
South Africa. More work will also be conducted on the integration of the MNS module of OHT into a 
broader, sector-wide analysis of health system constraints and needs; this requires more involved effort as 
the scope of analysis stretches to inclusion of other priority programmes. For example in the South African 
context, where an integrated approach to chronic disease management and prevention is being rolled 
out, findings and estimates from the MNS module can be linked to other disease-specific programme 
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needs, with a view to determining overall health system requirements for human resources, infrastructural 
development and financing.   
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Box 1 Contextualisation process: Ethiopia 
Background: The Ethiopian National Mental Health Strategy was published in 2012 and embraced a plan to scale-up 
mental health care based on the WHO mental health Gap Action Programme (mhGAP) and utilizing the mhGAP 
evidence-based packages of care for priority mental, neurological and substance use disorders. In 2014, the Ministry 
of Health of Ethiopia launched an ambitious 12 year plan to scale-up mental health care across the whole country. 
The Federal Ministry of Health of Ethiopia has adopted the OneHealth planning tool to support planning for its Health 
Sector Transformation Plan (2015/16 to 2019/20).  
Selecting priority MNS disorders: As part of the mhGAP pilot in Ethiopia, a prioritisation workshop of all relevant 
stakeholders was convened. At that workshop, the decision was made to focus on psychosis, epilepsy and 
depression. Alcohol use disorders were later added by the Ethiopia mhGAP working group. For the purpose of this 
current exercise the focus was on the three conditions initially prioritised by the FMOH of Ethiopia.   
Epidemiology: Ethiopia has a distinguished history in mental health research and it was therefore possible to make 
use of high quality epidemiological data from within country. Age- and sex-stratified data on the prevalence of 
schizophrenia, for example, was available from the Butajira Severe Mental Disorder study, in which more than 68000 
people were screened for psychosis and possible cases were investigated using gold standard clinician interviews 
(Kebede et al, 2000; Alem et al, 2009).  
Packages of care: The selection of packages of care for each of the three priority MNS disorders (psychosis, epilepsy 
and depression) was informed by the availability of appropriate human resources and learning from the Emerald-
affiliated Programme for Improving Mental health carE (PRIME) in Ethiopia (Hanlon et al, 2014). Although Ethiopia 
has very few specialist professionals who have the capacity to train, deliver or supervise intensive psychological 
therapies., the formative work for the PRIME study indicated that task sharing for intensive psychological therapies, 
for example with primary health nurses and community-based health workers, is not feasible. Therefore, for 
psychosis, we did not include intensive psychological therapy. For depression, intensive psychological therapy was 
felt to be appropriate and potentially feasible for a small proportion of people with moderate-severe depression, given 
the work underway to scale-up interpersonal therapy for depression in primary care settings (the Biaber project; 
http://mhinnovation.net/innovations/biaber-project) and the work in PRIME to develop feasible psychosocial 
interventions for depression. The medications used for each package were adapted to the Ethiopian setting, with a 
particular focus on medications which are likely to become available in the primary care setting. The costs of relevant 
psychotropic medications were obtained from the central Pharmaceutical Fund and Supply Agency. 
Coverage: Estimates of baseline coverage were obtained from Ethiopia research studies. The National Mental Health 
Strategy aspired to 50% coverage for all of the priority MNS disorders by the end of 2015. However, the more 
detailed mental health scale-up plan for Ethiopia aims for 44% coverage (at the health facility level) by the end of 
2019. Given the challenges experienced by the mhGAP pilot in Ethiopia and by the PRIME Ethiopia project with 
respect to demand for mental health care for depression, a modest coverage target of 30% by 2020 was set. For 
psychosis the target coverage was 30%, and for epilepsy the target coverage was 50%. The higher target for 
coverage for epilepsy reflected the lower baseline treatment gap and the success in the mhGAP pilot in delivering 
care to people with epilepsy in the primary care setting.  
Programme costs: Information on the programme specific staff inputs required for scale-up were obtained from the 
National Mental Health Strategy, for example, to include a new mental health co-ordinator at each level of the health 
system (district, regional and national). Furthermore, information on the training plans, in terms of the number of 
health workers per health centre per year were obtained from MoH plans developed within the NCD unity. 
Information on human resource costs, training costs for mhGAP and infrastructure costs were obtained from the 
planning department of the Ministry of Health.  
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Table 1 Current and target coverage levels of interventions for priority MNS disorders modelled in OHT (%) 
1 Exponential scale-up provides for an initially slow degree of health system development but then speeds up exponentially as the target year approaches; Linear 
scale-up assumes a constant rate of coverage expansion between baseline and target year.
 Ethiopia India Nepal Nigeria South Africa Uganda 
Interpolation type1 Exponential Exponential Linear Linear Linear Exponential 
 
Baseline 
coverage 
Target 
coverage 
Baseline 
coverage 
Target 
coverage 
Baseline 
coverage 
Target 
coverage 
Baseline 
coverage 
Target 
coverage 
Baseline 
coverage 
Target 
coverage 
Baseline 
coverage 
Target 
coverage 
Depression             
Basic psychosocial treatment for mild 
cases 
- - 10 30 - - - - - - 10 30 
Psychosocial treatment and anti-
depressant medication of first episode 
moderate-severe cases 
1 20 5 20 5 35 10 30 15 30 5 20 
Intensive psychosocial treatment and 
anti-depressant medication of first 
episode moderate-severe cases 
0.1 10   - - - - 5 15 5 20 
Psychosocial treatment and anti-
depressant medication of recurrent 
moderate-severe cases on an 
episodic basis 
0.1 10   5 35 10 30 - - 5 20 
Intensive psychosocial treatment and 
anti-depressant medication of 
recurrent moderate-severe cases on a 
maintenance basis 
0.1 10   - - - - - - 5 20 
Psychosis             
Basic psychosocial treatment and 
anti-psychotic medication 
2 30 20 50 20 50 20 50 20 50 20 50 
Intensive psychosocial treatment and 
anti-psychotic medication 
- - 5 20 - - - - 0 10 5 20 
Epilepsy             
Basic psychosocial support, advice 
and follow-up, plus anti-epileptic 
medication 
15 50 - - 40 80 20 60 - - 50 90 
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Table 2 Total costs (US$) 
Country  2014 2015 2016 2017 2018 2019 2020 Total 
Ethiopia Total $10,793,057 $15,994,423 $21,161,420 $26,896,829 $32,536,724 $38,359,656 $44,104,042 $189,846,151 
 Per capita $0.11 $0.16 $0.21 $0.25 $0.30 $0.34 $0.39 $1.76 
India Total $84,350,415  $102,692,518  $122,084,066  $142,116,507  $162,750,775  $181,410,772  $202,873,902  $998,278,955  
 Per capita $0.07  $0.08  $0.10  $0.11  $0.12  $0.14  $0.15  $0.77  
Nepal Total $9,123,511 $13,580,538 $18,105,276 $22,774,097 $27,590,348 $32,551,737 $37,527,394 $161,252,900 
 Per capita $0.33 $0.49 $0.64 $0.80 $0.95 $1.11 $1.27 $5.58 
Nigeria Total $240,290,580 $373,889,010 $529,966,888 $709,339,852 $911,992,658 $- $- $2,765,478,988 
 Per capita $1.36 $2.06 $2.84 $3.69 $4.61   $14.56 
South 
Africa 
Total $102,656,451 $124,426,615 $144,002,944 $170,362,472 $198,851,125 $228,849,571 $262,147,132 $1,320,179,429 
 Per capita $1.92 $2.29 $2.63 $3.07 $3.55 $4.05 $4.59 $23.81 
Uganda Total $6,742,625 $9,583,382 $11,725,832 $13,539,385 $14,987,252 $- $- $56,578,476 
 Per capita $0.18 $0.24 $0.29 $0.32 $0.34 - - $7.35 
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Table 3 Healthy life years gained – impact of scale-up 
Country Disorder 2014 2015 2016 2017 2018 2019 2020 Total 
Ethiopia Depression 
- 7,329 15,941 25,283 35,278 45,919 57,202 186,952 
 Psychosis 
- 983 2,047 3,199 4,443 5,769 7,186 23,627 
 Epilepsy 
- 5,702 10,474 14,432 17,671 20,212 22,107 90,598 
 Total 
- 14,014 28,462 42,914 57,392 71,900 86,495 301,177 
 Per 1m population 140 277 406 529 645 755  
India 1 Depression - 36,217 77,440 120,994 166,359 213,376 261,961 876,347 
 Psychosis - 19,357 39,510 60,471 82,250 104,676 127,811 434,075 
 Epilepsy n/a n/a n/a n/a n/a n/a n/a n/a 
 Total - 55,574 116,950 181,465 248,609 318,052 389,772 1,310,422 
 Per 1m population 44 91 140 190 240 291  
Nepal Depression - 1,985 4,239 6,632 9,137 11,746 14,453 48,192 
 Psychosis - 380 782 1,207 1,656 2,125 2,617 8,767 
 Epilepsy - 1,080 2,271 3,564 4,949 6,418 7,961 26,243 
 Total - 3,445 7,292 11,403 15,742 20,289 25,031 83,202 
 Per 1m population 123 258 398 544 693 844  
Nigeria Depression - 10,200 21,928 34,486 47,789 - - 114,403 
 Psychosis - 3,512 7,253 11,241 15,493 - - 37,499 
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 Epilepsy - 17,741 32,960 45,987 57,070 - - 153,758 
 Total - 31,453 62,141 91,714 120,352 - - 305,660 
 Per 1m population 173 333 477 609    
South Africa Depression - 2,685 5,880 9,305 12,906 16,673 20,603 68,052 
 Psychosis - 216 445 684 935 1,197 1,470 4,947 
 Epilepsy n/a n/a n/a n/a n/a n/a n/a n/a 
 Total - 2,901 6,325 9,989 13,841 17,870 22,073 72,999 
 
Per 1m 
population 
54 117 182 250 319 390 463  
Uganda Depression - 5,290 11,505 18,246 25,467 - - 60,508 
 Psychosis - 989 2,057 3,210 4,454 - - 10,710 
 Epilepsy - 3,699 6,795 9,370 11,485 - - 31,349 
 Total - 9,978 20,357 30,826 41,406 - - 102,567 
 Per 1m population 253 499 730 947    
1 Population refers to the State of Madhya Pradesh 
 
 
  
 
 
17 
 
 
 
Figure 1 Distribution of total costs of service scale-up for psychosis, depression and epilepsy 
 
  
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Ethiopia
India
Nepal
Nigeria
South Africa
Uganda
Distribution of total costs
Drugs and supplies Ambulatory and outpatient care Inpatient care Programme costs
 
 
18 
 
 
WEB APPENDIX Table A Intervention effect size estimates for MND disorders module 
 
DEPRESSION 
Intervention mhGAP-IG ref Impacts on Efficacy  
(% improvement) 
Adherence 
(%) 
Effectiveness 
(Efficacy * adherence) 
Data source(s) 
Basic psychosocial treatment & 
anti-depressant medication DEP2 & DEP3 Remission 
35% [from a remission of 2.0 
to 2.7 (per 1 person)] 
60% 
21%  
(35%*60%) 
Chisholm et al, Br J 
Psychiatry 2004 
Intensive psychosocial treatment 
& anti-depressant medication DEP3 & INT Remission 
35% [from a remission of 2.0 
to 2.7 (per 1 person)] 
70% 
24.5%  
(35%*70%) 
Chisholm et al, Br J 
Psychiatry 2004 
Psychosocial treatment for peri-
natal depression  Remission 
30% [relative risk of 0.7, or 
moving from a remission of 
2.0 to 2.6 (per 1 person) 
80% 
24%  
(30%*80%) 
 
 
PSYCHOSIS 
Intervention mhGAP-IG ref Impacts on Efficacy  
(% improvement) 
Adherence 
(%) 
Effectiveness 
(Efficacy * adherence) 
Data source(s) 
Basic psychosocial support & 
anti-psychotic medication PSY2 & PSY3 
Functioning 
(reduced disability) 
8.4% [from a disability weight 
of 0.627 to 0.574] 
70% 
5.9%  
8.4%*70%) 
Chisholm et al, 
WHO Bulletin 2008 
Intensive psychosocial support & 
anti-psychotic medication DEP3 & INT 
Functioning 
(reduced disability) 
14.3% [from a disability 
weight of 0.627 to 0.537] 
70% 
10.0%  
(14.3%*70%) 
Chisholm et al, 
WHO Bulletin 2008 
 
EPILEPSY 
Intervention mhGAP-IG ref Impacts on Efficacy  
(% improvement) 
Adherence 
(%) 
Effectiveness 
(Efficacy * adherence) 
Data source(s) 
Basic psychosocial support & 
anti-epileptic medication 
EPI2  Remission 
60% [0.09 to 0.05 (per 1 
person), adjusted for 25% 
non-response] 
70% 
42.0%  
(60%*70%) 
Chisholm et al, 
Epilepsia 2005 
EPI2 Functioning 
(reduced disability) 
57% [from a disability weight 
of 0.3 to 0.13, adjusted for 
25% non-response] 
70% 
39.9%  
(57%*70%) 
Chisholm et al, 
Epilepsia 2005 
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Web Appendix Table B Total drugs and supplies costs (US$) 
Country Disorder 2014 2015 2016 2017 2018 2019 2020 Total 
Ethiopia Depression 
 $48,953   $332,832   $624,719   $924,167   $1,230,798   $1,544,406   $1,865,582   $6,571,458  
 Psychosis 
 $62,325   $209,321   $358,039   $507,761   $657,668   $806,841   $954,348   $3,556,303  
 Epilepsy 
 $10,199,019   $14,196,875   $18,235,852   $22,330,568   $26,494,718   $30,717,772   $35,003,953   $157,178,757  
 Total 
 $10,310,297   $14,739,028   $19,218,610   $23,762,496   $28,383,183   $33,069,019   $37,823,883   $167,306,517  
India Depression $4,095,448 $3,150,874 $3,981,083 $5,059,723 $6,279,568 $7,576,342 $10,104,493 $40,247,532 
 Psychosis $1,163,219 $1,146,274 $1,471,055 $1,785,299 $2,085,278 $2,368,588 $2,954,006 $12,973,719 
 Epilepsy n/a n/a n/a n/a n/a n/a n/a n/a 
 Total $5,258,667 $4,297,149 $5,452,138 $6,845,022 $8,364,846 $9,944,930 $13,058,499 $53,221,251 
Nepal Depression $249,938 $491,533 $732,490 $970,950 $1,205,634 $1,435,816 $1,661,202 $6,747,563 
 Psychosis $1,216,607 $1,571,802 $1,949,231 $2,349,649 $2,773,807 $3,222,351 $3,695,899 $16,779,346 
 Epilepsy $3,065,621 $3,619,745 $4,170,689 $4,714,166 $5,246,278 $5,760,635 $6,253,756 $32,830,890 
 Total  $4,532,166   $5,683,080   $6,852,410   $8,034,764   $9,225,720   $10,418,801   $11,610,856   $56,357,798  
Nigeria Depression  $3,023,818   $8,470,229   $16,784,590   $28,147,846   $42,745,997   $-     $-     $99,172,481  
 Psychosis  $2,107,649   $4,486,390   $7,855,520   $12,299,368   $17,905,856   $-     $-     $44,654,783  
 Epilepsy  $16,883,786   $38,125,719   $68,115,271   $107,087,938   $155,325,559   $-     $-     $385,538,272  
 Total  $22,015,253   $51,082,338   $92,755,382   $147,535,153   $215,977,412   $-     $-     $529,365,537  
South 
Africa 
Depression $1,468,526 $1,705,021 $1,946,411 $2,195,634 $2,451,461 $2,714,267 $2,983,697 $16,741,035 
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 Psychosis $875,267 $1,054,830 $1,237,681 $1,423,383 $1,611,551 $1,806,268 $2,011,674 $10,719,766 
 Epilepsy n/a n/a n/a n/a n/a n/a n/a n/a 
 Total $2,343,792 $2,759,851 $3,184,093 $3,619,017 $4,063,012 $4,520,535 $4,995,372 $27,460,801 
Uganda Depression $690,765 $1,136,975 $1,557,131 $1,947,980 $2,306,685 $- $- $7,639,536 
 Psychosis $415,581 $602,168 $786,656 $967,454 $1,142,818 $- $- $3,914,678 
 Epilepsy $1,988,803 $2,414,554 $2,853,554 $3,309,564 $3,789,023 $- $- $14,355,499 
 Total $3,095,150 $4,153,696 $5,197,342 $6,224,998 $7,238,526 $- $- $25,909,713 
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Web Appendix Table C Cost of outpatient and ambulatory care (US$) 
 
Country Disorder 2014 2015 2016 2017 2018 2019 2020 Total 
Ethiopia Depression  $6,439   $22,773   $41,056   $61,428   $84,032   $109,011   $136,521   $461,260  
 Psychosis  $23,807   $268,655   $527,135   $799,290   $1,085,189   $1,384,998   $1,699,651   $5,788,724  
 Epilepsy  $139,174   $195,726   $254,006   $314,255   $376,706   $441,250   $507,987   $2,229,105  
 Total  $169,420   $487,155   $822,197   $1,174,972   $1,545,927   $1,935,259   $2,344,160   $8,479,089  
India Depression  $2,400,659   $3,088,415   $3,735,371   $4,304,677   $4,770,652   $5,107,740   $5,289,894   $28,697,409  
 Psychosis  $927,998   $1,242,694   $1,596,561   $1,992,994   $2,435,612   $2,928,249   $3,475,053   $14,599,159  
 Epilepsy n/a n/a n/a n/a n/a n/a n/a n/a 
 Total  $3,328,657   $4,331,109   $5,331,931   $6,297,671   $7,206,264   $8,035,989   $8,764,947   $43,296,568  
Nepal Depression  $1,140,871   $2,298,207   $3,511,435   $4,777,164   $6,094,733   $7,466,425   $8,897,256   $34,186,090  
 Psychosis  $476,008   $624,235   $786,526   $964,248   $1,158,996   $1,372,568   $1,607,051   $6,989,632  
 Epilepsy  $633,546   $784,007   $949,348   $1,130,973   $1,330,576   $1,549,424   $1,789,677   $8,167,550  
 Total  $2,250,424   $3,706,449   $5,247,309   $6,872,383   $8,584,304   $10,388,417   $12,293,984   $49,343,272  
Nigeria Depression 
 
$24,720,677  
 $38,006,463   $52,102,053   $66,989,865   $82,686,481   $-     $-     $264,505,539  
 Psychosis  $4,205,069   $8,066,367   $13,349,693   $20,174,538   $28,665,537   $-     $-     $74,461,205  
 Epilepsy 
 
$14,039,337  
 $25,774,337   $40,754,255   $59,080,290   $80,868,525   $-     $-     $220,516,745  
 Total 
 
$42,965,083  
$71,847,166  
 
$106,206,002  
 
$146,244,694  
 
$192,220,544  
 $-     $-     $559,483,488  
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South 
Africa 
Depression 
 
$72,656,028  
 $86,102,595  
 
$100,876,470  
 
$116,914,760  
 
$134,256,370  
 
$153,025,654  
 
$174,724,837  
 $900,762,946  
 Psychosis 
 
$22,104,362  
 $27,614,020   $28,747,123   $34,861,717   $41,721,238   $49,406,258   $60,063,553   $284,321,363  
 Epilepsy n/a n/a n/a n/a n/a n/a n/a n/a 
 Total 
 
$94,760,390  
 
$113,716,615  
 
$129,623,593  
 
$151,776,477  
 
$175,977,609  
 
$202,431,912  
 
$234,788,390  
 
$1,185,084,308  
Uganda Depression  $1,177,316   $1,778,480   $2,193,514   $2,410,486   $2,418,215   $-     $-     $9,978,009  
 Psychosis  $232,991   $356,829   $482,619   $616,279   $759,283   $-     $-     $2,448,001  
 Epilepsy  $710,607   $865,079   $1,025,653   $1,193,238   $1,368,733   $-     $-     $5,163,311  
 Total  $2,120,914   $3,000,388   $3,701,786   $4,220,002   $4,546,231   $-     $-     $17,589,321  
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Web Appendix Table D Cost of inpatient days (US$) 
 
Country Disorder 2014 2015 2016 2017 2018 2019 2020 Total 
Ethiopia Depression  $13,307   $238,575   $474,382   $720,637   $977,275   $1,244,325   $1,522,501   $5,191,002  
 Psychosis  $25,196   $76,978   $117,733   $145,860   $159,672   $157,396   $137,198   $820,033  
 Epilepsy $0 $0 $0 $0 $0 $0 $0 $0 
 Total  $38,502   $315,553   $592,115   $866,497   $1,136,948   $1,401,720   $1,659,700   $6,011,035  
India Depression $0 $0 $0 $0 $0 $0 $0 $0 
 Psychosis $51,824,184 $66,103,928 $80,894,731 $96,184,840 $111,961,572 $128,210,637 $144,919,908 $680,099,799 
 Epilepsy n/a n/a n/a n/a n/a n/a n/a n/a 
 Total $51,824,184 $66,103,928 $80,894,731 $96,184,840 $111,961,572 $128,210,637 $144,919,908 $680,099,799 
Nepal Depression  $1,462,295   $2,926,158   $4,438,364   $5,990,075   $7,575,451   $9,191,737   $10,838,804   $42,422,884  
 Psychosis  $878,626   $1,144,979   $1,431,295   $1,737,963   $2,065,386   $2,413,872   $2,783,749   $12,455,868  
 Epilepsy $0 $0 $0 $0 $0 $0 $0 $0 
 Total  $2,340,920   $4,071,137   $5,869,659   $7,728,039   $9,640,837   $11,605,608   $13,622,553   $54,878,753  
Nigeria Depression  $27,767,752   $42,426,654   $57,799,896   $73,851,983   $90,585,438   $-     $-     $292,431,723  
 Psychosis  $143,715,801   $203,944,469   $267,825,026   $335,466,371   $406,986,534   $-     $-     $1,357,938,201  
 Epilepsy $0 $0 $0 $0 $0 - - $0 
 Total  $171,483,553   $246,371,122   $325,624,922   $409,318,354   $497,571,973   $-     $-     $1,650,369,924  
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South Africa Depression n/a n/a n/a n/a n/a n/a n/a n/a 
 Psychosis $1,538,970 $1,787,024 $1,964,853 $2,065,926 $2,084,008 $2,013,331 $1,848,010 $14,529,154 
 Epilepsy n/a n/a n/a n/a n/a n/a n/a n/a 
 Total $1,538,970 $1,787,024 $1,964,853 $2,065,926 $2,084,008 $2,013,331 $1,848,010 $14,529,154 
Uganda Depression $670,694 $979,367 $1,152,412 $1,178,674 $1,046,949 $- $- $5,028,096 
 Psychosis $519,525 $757,348 $996,501 $1,235,474 $1,472,602 $- $- $4,981,450 
 Epilepsy $0 $0 $0 $0 $0 - - $0 
 Total $1,190,219 $1,736,715 $2,148,914 $2,414,148 $2,519,550 $- $- $10,009,546 
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Web Table E Programme costs (US$) 
Country 2014 2015 2016 2017 2018 2019 2020 Total 
Ethiopia $274,838 $452,687 $528,498 $1,092,864 $1,470,666 $1,953,657 $2,276,300 $8,049,510 
India $17,583,000 $17,233,000 $17,233,000 $17,233,000 $17,233,000 $14,695,000 $14,430,000 $115,640,000 
Nepal $- $119,872 $135,897 $138,910 $139,487 $138,910 $- $673,077 
Nigeria $3,826,692 $4,588,384 $5,380,582 $6,241,651 $6,222,730 $- $- $26,260,039 
South 
Africa 
$4,013,297 $6,163,126 $9,230,405 $12,901,051 $16,726,496 $19,883,793 $20,515,360 $93,105,166 
Uganda $336,342 $692,582 $677,790 $680,237 $682,945 $- $- $3,069,896 
 
